BEIJING (Reuters) – China has suspended the import, sale and use of Daewoong Bio’s cefodizime sodium for injection, after the South Korean company rejected an inspection request at its production site, the Chinese medical regulator said on Thursday.
Daewoong Bio’s move violated China’s Drug Administration Law and regulations on overseas inspection of drugs and medical devices, the National Medical Products Administration said in a statement.
Cefodizime sodium is an antibiotic that treats a variety of bacterial infections and is sometimes prescribed for people who are allergic to penicillin, another form of antibiotic.
(Reporting by Ethan Wang and Ryan Woo; Editing by Kirsten Donovan)
Comments